Suppr超能文献

高纯度凝血因子IX浓缩物的生化特性及体内特性

Biochemical and in vivo properties of high purity factor IX concentrates.

作者信息

Berntorp E, Björkman S, Carlsson M, Lethagen S, Nilsson I M

机构信息

Department for Coagulation Disorders, University of Lund, Sweden.

出版信息

Thromb Haemost. 1993 Nov 15;70(5):768-73.

PMID:8128433
Abstract

The purified factor IX concentrates Nanotiv (Kabi Pharmacia), Immunine (Immuno), Factor IX VHP (Bio-transfusion), Alphanine (Alpha) and Mononine (Armour) have been studied in vitro and compared with the prothrombin complex concentrates (PCCs) Preconativ (Kabi Pharmacia) and Prothromplex TIM4 (Immuno). The measured values for factor IX coagulant activity (IX:C) were in good agreement with the manufacturer's label values. In contrast to the PCCs, most of the purified concentrates were virtually devoid of other vitamin K-dependent coagulation factors, the inhibitors protein C and S as well as fibrinogen, fibronectin and immunoglobulins. Indicators of thrombin generation, namely prothrombin fragments 1 and 2 (F 1 + 2) and thrombin-antithrombin complex (TAT), were present in varying amounts in all preparations. The specific activity in the purified concentrates exceeded that in the PCCs by a factor of 50-100. Some differences in purity were found between the purified concentrates. In vivo, Nanotiv was compared with Preconativ and Immunine with Prothromplex TIM4 in crossover studies in patients with severe hemophilia B, and Mononine was tested in a single drug study. Most of the preparations yielded postinfusion increases in TAT, but not in F 1 + 2. Pharmacokinetic variables were analyzed with non-linear curve-fitting combined with model-independent methods. In retrospective comparisons, there were no apparent differences between Nanotiv, Preconativ and Mononine, whereas in vivo recovery seemed lower and the apparent clearance higher for Immunine and Prothromplex. Purified factor IX concentrates were successfully used as cover for surgery or in immune tolerance induction.

摘要

已对纯化的凝血因子IX浓缩剂Nanotiv(卡比- Pharmacia公司)、Immunine(Immuno公司)、Factor IX VHP(生物输血公司)、Alphanine(阿尔法公司)和Mononine(阿莫尔公司)进行了体外研究,并与凝血酶原复合物浓缩剂(PCCs)Preconativ(卡比- Pharmacia公司)和Prothromplex TIM4(Immuno公司)进行了比较。凝血因子IX促凝活性(IX:C)的测量值与制造商标签值高度一致。与PCCs不同的是,大多数纯化浓缩剂几乎不含其他维生素K依赖的凝血因子、蛋白C和S抑制剂以及纤维蛋白原、纤连蛋白和免疫球蛋白。所有制剂中均存在不同量的凝血酶生成指标,即凝血酶原片段1和2(F 1 + 2)以及凝血酶-抗凝血酶复合物(TAT)。纯化浓缩剂的比活性比PCCs高50至100倍。发现纯化浓缩剂之间在纯度上存在一些差异。在体内,在重度B型血友病患者的交叉研究中,将Nanotiv与Preconativ进行了比较,将Immunine与Prothromplex TIM4进行了比较,并且在单一药物研究中对Mononine进行了测试。大多数制剂在输注后TAT升高,但F 1 + 2未升高。采用非线性曲线拟合结合非模型依赖方法对药代动力学变量进行了分析。在回顾性比较中,Nanotiv、Preconativ和Mononine之间没有明显差异,而Immunine和Prothromplex的体内回收率似乎较低,表观清除率较高。纯化的凝血因子IX浓缩剂已成功用于手术覆盖或免疫耐受诱导。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验